<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Amisulpride" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Amisulpride</book-part-id>
      <title-group>
        <title>Amisulpride</title>
        <subtitle>Short Chapter</subtitle>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Amiodarone" document-type="chapter">Amiodarone</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Amitriptyline" document-type="chapter">Amitriptyline</related-object>
    </book-part-meta>
    <body>
      <p><italic toggle="yes">[Preliminary review chapter based on the FDA Product Labeling and Integrated Review</italic>
<italic toggle="yes">only.]</italic></p>
      <sec id="Amisulpride.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Amisulpride.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Amisulpride is an intravenously administered dopamine receptor 2 antagonist used for the prevention and therapy of postoperative nausea and vomiting. Amisulpride when given in single doses intravenously has not been associated with serum aminotransferase elevations or with instances of clinically apparent liver.</p>
        </sec>
        <sec id="Amisulpride.Background">
          <title>Background</title>
          <p>Amisulpride (a&#x0201d; mi sul&#x02019; pride) is a dopamine receptor type 2 (DR2) antagonist used for the prevention and therapy of postoperative nausea and vomiting. Amisulpride blocks dopamine receptors found in the chemoreceptor trigger zone in the hypothalamus that relays stimuli to the vomiting center. In several controlled trials, administration of a single intravenous dose of amisulpride at the time of induction of anesthesia for surgery reduced nausea and vomiting during the 24 to 48 hours thereafter. Similarly, administration of a single intravenous dose after onset of nausea reduced the frequency and severity of subsequent nausea and vomiting. Amisulpride can be given orally and is approved as an oral antipsychotic medication in Europe, but not in the United States. Intravenously administered amisulpride was approved in the United States in 2020 for prevention of postoperative nausea and vomiting either alone or in combination with an antiemetic of a different class or for treatment of postoperative nausea and vomiting in patients who did not receive preventive therapy or received another class of antiemetics. Amisulpride is available in solution for intravenous administration in vials of 2 and 4 mL (2.5 mg/mL) under the brand name Barhemsys. The recommended dose for prevention is 5 mg (2 mL) and for therapy of nausea and vomiting is 10 mg (4 mL). Amisulpride given in a single intravenous dose has few adverse events. While oral amisulpride, like other dopamine receptor antagonists, has been linked to rare instances of extrapyramidal side effects and neuroleptic malignant syndrome, these severe adverse events have not been found to be associated with its use in single doses given intravenously. Amisulpride has been linked to prolongation of the QTc interval and should be avoided in patients with known prolonged QTc intervals or in patients receiving other agents that can prolong the QTc interval as well as other dopamine antagonists.</p>
        </sec>
        <sec id="Amisulpride.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Intravenous single doses of amisulpride are generally well tolerated, and in multiple randomized controlled trials were not associated with rates of serum aminotransferase or bilirubin elevations above those that occurred in placebo treated subjects. While oral amisulpride has been linked to transient serum aminotransferase elevations during therapy, single intravenous doses of amisulpride have not been linked to liver enzyme elevations in excess of rates found postoperatively. Since its approval and more widespread use, amisulpride has not been implicated in cases of clinically apparent liver injury.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Amisulpride.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The possible mechanism of liver injury from amisulpride is not known, but liver test abnormalities can occur with prolonged oral dosing. Oral amisulpride can also cause extrapyramidal symptoms and neuroleptic malignant syndrome, probably due to excessive dopamine receptor antagonism. Amisulpride is not metabolized to a great extent by the liver, is not a substrate of the P450 system, and has no interaction with CYP enzyme activities.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="GastrointestinalAgen" document-type="book-part">Gastrointestinal Agents</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="AntiemeticAgents" document-type="book-part">Antiemetic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Amisulpride.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Amisulpride &#x02013; Barhemsys&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Antiemetic Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Amisulpride">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Amisulpride.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Amisulpride.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Amisulpride.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Amisulpride.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Amisulpride.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Amisulpride.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Amisulpride.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Amisulpride</td>
                <td headers="hd_h_Amisulpride.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135027384">71675-85-9</ext-link>
</td>
                <td headers="hd_h_Amisulpride.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C17-H27-N3-O4-S</td>
                <td headers="hd_h_Amisulpride.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135027384" document-id-type="sid" document-type="summary" object-id="135027384" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Amisulpride.BIBLIOGRAPHY">
        <title>BIBLIOGRAPHY</title>
        <p>References updated: 28 April 2024</p>
        <p><bold><italic toggle="yes">[Short Chapter</italic></bold>
<italic toggle="yes">information is based largely on FDA Product Labeling and the FDA Integrated Review accessible from the FDA website</italic>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm"><italic toggle="yes">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</italic></ext-link><italic toggle="yes">. All other references have not been fully reviewed and annotated.]</italic></p>
        <ref-list id="Amisulpride.BIBLIOGRAPHY.reflist0">
          <ref id="Amisulpride.REF.fda.2020">
            <mixed-citation publication-type="journal"><collab>FDA</collab>. <source>Integrated Review.</source>
<year>2020</year>.</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF2">
            <mixed-citation publication-type="web">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209510Orig1s000MultidisciplineR.pdf</ext-link>
<annotation><p>
<italic toggle="yes">(FDA integrated review of the data on safety and efficacy of intravenous amisulpride submitted in support of the application for approval as therapy of postoperative nausea and vomiting states that among 1924 patients who received amisulpride there were &#x0201c;no clinically important changes in clinical chemistry values between baseline and post operation&#x0201d; and that extrapyramidal symptoms were uncommon and mild, and rates were similar between placebo and amisulpride treated patients).</italic>
</p></annotation>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.coulouvrat.1999.209">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Coulouvrat</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dondey-Nouvel</surname>
<given-names>L.</given-names></string-name>
<article-title>Safety of amisulpride (Solian): a review of 11 clinical studies.</article-title>
<source>Int Clin Psychopharmacol.</source>
<year>1999</year>;<volume>14</volume>:<fpage>209</fpage>-<lpage>18</lpage>.<pub-id pub-id-type="pmid">10468313</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.mortimer.2004.63">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mortimer</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>L&#x000f4;o</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Peuskens</surname>
<given-names>J</given-names></string-name>; <collab>SOLIANOL Study Group</collab>. <article-title>A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.</article-title>
<source>Int Clin Psychopharmacol.</source>
<year>2004</year>;<volume>19</volume>:<fpage>63</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">15076013</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.musshoff.2013.218">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Musshoff</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Doberentz</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Madea</surname>
<given-names>B</given-names></string-name>. <article-title>Lethal neuroleptic malignant syndrome due to amisulpride.</article-title>
<source>Forensic Sci Med Pathol.</source>
<year>2013</year>;<volume>9</volume>:<fpage>218</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">23504701</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.gan.2017.268">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gan</surname>
<given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Kranke</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Minkowitz</surname>
<given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Bergese</surname>
<given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Motsch</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eberhart</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leiman</surname>
<given-names>DG</given-names></string-name>, <etal>et al.</etal>
<article-title>Intravenous amisulpride for the prevention of postoperative nausea and vomiting: two concurrent, randomized, double-blind, placebo-controlled trials.</article-title>
<source>Anesthesiology.</source>
<year>2017</year>;<volume>126</volume>:<fpage>268</fpage>-<lpage>275</lpage>.<pub-id pub-id-type="pmid">27902493</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.kranke.2018.1099">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kranke</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bergese</surname>
<given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Minkowitz</surname>
<given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Melson</surname>
<given-names>TI</given-names></string-name>, <string-name name-style="western"><surname>Leiman</surname>
<given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Candiotti</surname>
<given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Eberhart</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Habib</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Wallenborn</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kovac</surname>
<given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Diemunsch</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname>
<given-names>TJ</given-names></string-name>. <article-title>Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial.</article-title>
<source>Anesthesiology.</source>
<year>2018</year>
<month>Jun</month>;<volume>128</volume>(<issue>6</issue>):<fpage>1099</fpage>-<lpage>1106</lpage>.<pub-id pub-id-type="pmid">29543631</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.habib.2019.203">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Habib</surname>
<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Kranke</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bergese</surname>
<given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ayad</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Motsch</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial.</article-title>
<source>Anesthesiology.</source>
<year>2019</year>;<volume>130</volume>:<fpage>203</fpage>-<lpage>212</lpage>.<pub-id pub-id-type="pmid">30475232</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.candiotti.2019.1098">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Candiotti</surname>
<given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Kranke</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bergese</surname>
<given-names>SD</given-names></string-name>, <string-name name-style="western"><surname>Melson</surname>
<given-names>TI</given-names></string-name>, <string-name name-style="western"><surname>Motsch</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Siddiqui</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Amisulpride as Treatment of Established Postoperative Nausea and Vomiting in Patients Who Have Had No Prior Prophylaxis.</article-title>
<source>Anesth Analg.</source>
<year>2019</year>;<volume>128</volume>:<fpage>1098</fpage>-<lpage>1105</lpage>.<pub-id pub-id-type="pmid">31094774</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.herrstedt.2019.2699">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Herrstedt</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Summers</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jordan</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>von Pawel</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jakobsen</surname>
<given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Ewertz</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.</article-title>
<source>Support Care Cancer.</source>
<year>2019</year>;<volume>27</volume>:<fpage>2699</fpage>-<lpage>2705</lpage>.<pub-id pub-id-type="pmid">30488222</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.amisulpride.2020.205">
            <mixed-citation publication-type="journal"><string-name name-style="western"><given-names>IV</given-names>
<surname>Amisulpride</surname></string-name>
<article-title>(Barhemsys) for postoperative nausea and vomiting.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2020</year>;<volume>62</volume>:<fpage>205</fpage>-<lpage>208</lpage>.<pub-id pub-id-type="pmid">33451177</pub-id>
</mixed-citation>
          </ref>
          <ref id="Amisulpride.REF.zeiss.2022.440">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zeiss</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hafner</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sch&#x000f6;nfeldt-Lecuona</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Connemann</surname>
<given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Gahr</surname>
<given-names>M</given-names></string-name>. <article-title>Drug-associated liver injury related to antipsychotics: exploratory analysis of pharmacovigilance data.</article-title>
<source>J Clin Psychopharmacol.</source>
<year>2022</year>;<volume>42</volume>:<fpage>440</fpage>-<lpage>444</lpage>.<pub-id pub-id-type="pmid">35730552</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Amisulpride.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Amisulpride+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Amisulpride: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Amisulpride">Trials on Amisulpride: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
